Spray-dried raloxifene submicron particles for pulmonary delivery: Development and in vivo pharmacokinetic evaluation in rats

Fontana, Márcia Camponogara; Laureano, João Víctor; Forgearini, Betielli; Santos, Juliana dos; Pohlmann, Adriana Raffin; Guterres, Sı́lvia Stanisçuaski; Araújo, Bibiana Verlindo de; Beck, Ruy Carlos Ruver

doi:10.1016/j.ijpharm.2020.119429

Cited by 13 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SDDS are widely used to improve the solubility of poorly water-soluble drugs and have the advantage of improving oral bioavailability and enhancing skin permeability [ 60 ]. Formulating poorly water-soluble drugs such as raloxifene, icariin, and tocotrienol into liposomes or micro/nanoemulsions can increase their exposure levels in application sites, hence the bioavailability [ 61 ]. For example, Zakir et al [ 62 ] developed a formulation of nanoemulsion-based gels for transdermal delivery of raloxifene.…”

Section: Engineering Of Anti-op Drugs Deliverymentioning

confidence: 99%

Drug Delivery and Therapy Strategies for Osteoporosis Intervention

Ma,

Zeng,

Yang

et al. 2023

Molecules

View full text Add to dashboard Cite

With the advent of the aging society, osteoporosis (OP) risk increases yearly. Currently, the clinical usage of anti-OP drugs is challenged by recurrent side effects and poor patient compliance, regardless of oral, intravenous, or subcutaneous administration. Properly using a drug delivery system or formulation strategy can achieve targeted drug delivery to the bone, diminish side effects, improve bioavailability, and prolong the in vivo residence time, thus effectively curing osteoporosis. This review expounds on the pathogenesis of OP and the clinical medicaments used for OP intervention, proposes the design approach for anti-OP drug delivery, emphatically discusses emerging novel anti-OP drug delivery systems, and enumerates anti-OP preparations under clinical investigation. Our findings may contribute to engineering anti-OP drug delivery and OP-targeting therapy.

show abstract

Section: Engineering Of Anti-op Drugs Deliverymentioning

confidence: 99%

Drug Delivery and Therapy Strategies for Osteoporosis Intervention

Ma,

Zeng,

Yang

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

“…The liposomal surface charge determines the interaction of liposomes with tissues and cells, which can affect the safety issues [33,34]. Some negative effects of liposomes, especially cationic liposomes, have been observed [11,35,36]. Modification of the liposome surface to improve its properties, such as immunocompatibility, for example, with a polyethylene glycol coating, has also opened new horizons [37].…”

Section: Nanoliposomesmentioning

confidence: 99%

“…In addition, this functionalization of the surface of the nanoparticles, the modification of the surface charge, and the modulation of its size allow the therapeutic action to be directed to specific tissues and also to modify different pharmacokinetic parameters, such as half-life and bioavailability. These characteristics play a key role in the design of new theranostic therapies or drugs [8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials

Taléns‐Visconti

Dı́ez-Sales

Julián-Ortiz

et al. 2022

IJMS

View full text Add to dashboard Cite

The drugs used for cancer treatment have many drawbacks, as they damage both tumor and healthy cells and, in addition, they tend to be poorly soluble drugs. Their transport in nanoparticles can solve these problems as these can release the drug into tumor tissues, as well as improve their solubility, bioavailability, and efficacy, reducing their adverse effects. This article focuses on the advantages that nanotechnology can bring to medicine, with special emphasis on nanoliposomes. For this, a review has been made of the nanoliposomal systems marketed for the treatment of cancer, as well as those that are in the research phase, highlighting the clinical trials being carried out. All marketed liposomes studied are intravenously administered, showing a reduced intensity of side-effects compared with the nonliposomal form. Doxorubicin is the active ingredient most frequently employed. Ongoing clinical trials expand the availability of liposomal medicines with new clinical indications. In conclusion, the introduction of drugs in nanoliposomes means an improvement in their efficacy and the quality of life of patients. The future focus of research could be directed to develop multifunctional targeted nanoliposomes using new anticancer drugs, different types of existing drugs, or new standardized methodologies easily translated into industrial scale.

show abstract

“…As the number of THAs grows, total hip arthroplasty revision (THAR), a procedure that may occur due to prosthetic-related complications like joint stiffness, periprosthetic fracture, periprosthetic joint dislocation, and mechanical unraveling, has been increasingly performed around the world [1]. Unfortunately, with the increasing frequency of THARs, complications are more prevalent [3].…”

Section: Introductionmentioning

confidence: 99%

Incidence and risk factors of postoperative pulmonary complications following total hip arthroplasty revision: a retrospective Nationwide Inpatient Sample database study

Huang,

Lin

et al. 2024

J Orthop Surg Res

View full text Add to dashboard Cite

Background Postoperative pulmonary complications (PPCs) are among the most severe complications following total hip arthroplasty revision (THAR), imposing significant burdens on individuals and society. This study examined the prevalence and risk factors of PPCs following THAR using the NIS database, identifying specific pulmonary complications (SPCs) and their associated risks, including pneumonia, acute respiratory failure (ARF), and pulmonary embolism (PE). Methods The National Inpatient Sample (NIS) database was used for this cross-sectional study. The analysis included patients undergoing THAR based on NIS from 2010 to 2019. Available data include demographic data, diagnostic and procedure codes, total charges, length of stay (LOS), hospital information, insurance information, and discharges. Results From the NIS database, a total of 112,735 THAR patients in total were extracted. After THAR surgery, there was a 2.62% overall incidence of PPCs. Patients with PPCs after THAR demonstrated increased LOS, total charges, usage of Medicare, and in-hospital mortality. The following variables have been determined as potential risk factors for PPCs: advanced age, pulmonary circulation disorders, fluid and electrolyte disorders, weight loss, congestive heart failure, metastatic cancer, other neurological disorders (encephalopathy, cerebral edema, multiple sclerosis etc.), coagulopathy, paralysis, chronic pulmonary disease, renal failure, acute heart failure, deep vein thrombosis, acute myocardial infarction, peripheral vascular disease, stroke, continuous trauma ventilation, cardiac arrest, blood transfusion, dislocation of joint, and hemorrhage. Conclusions Our study revealed a 2.62% incidence of PPCs, with pneumonia, ARF, and PE accounting for 1.24%, 1.31%, and 0.41%, respectively. A multitude of risk factors for PPCs were identified, underscoring the importance of preoperative optimization to mitigate PPCs and enhance postoperative outcomes.

show abstract

Spray-dried raloxifene submicron particles for pulmonary delivery: Development and in vivo pharmacokinetic evaluation in rats

Cited by 13 publications

References 34 publications

Drug Delivery and Therapy Strategies for Osteoporosis Intervention

Drug Delivery and Therapy Strategies for Osteoporosis Intervention

Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials

Incidence and risk factors of postoperative pulmonary complications following total hip arthroplasty revision: a retrospective Nationwide Inpatient Sample database study

Contact Info

Product

Resources

About